Medical professionals who see many patients (primary care physicians and general practitioners) or who regularly treat patients with dysthyroid conditions (endocrinologists) play an important role in ...

Thyroid eye disease (TED) presents with a broad and heterogeneous constellation of ocular and periocular signs and symptoms. These manifestations are the result of the underlying autoimmune ...

—Even long after the active phase of thyroid eye disease has subsided, a multitude of challenging quality-of-life issues may persist. Several recent studies have established that the physical ...

After thyroid eye disease (TED) is diagnosed and patients are started on initial treatment options, clinicians next have to focus on long-term management of the condition. "Long-term care for TED ...

Most patients with thyroid eye disease treated with teprotumumab didn't require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ENDO 2024 ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Findings from THRIVE showed treatment with veligrotug led to statistically significant improvements in the signs and symptoms of TED. Topline data were announced from a phase 3 study evaluating ...

Shares rise 14% as drug meets main and secondary goals Analysts highlight less frequent dosing as a key advantage Jefferies estimates potential peak sales of $2 billion Sept 10 (Reuters) - Viridian ...

A study reveals nearly a quarter of patients treated with teprotumumab for thyroid eye disease require re-treatment within a year, and older patients are more likely to require additional treatment.

Under-eye swelling is a common cosmetic concern. Puffiness after a late night, salty meal, or crying usually clears up within a day. Discharge, pain, and other severe symptoms warrant an appointment ...

BOSTON—Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ...